Cardiology still a leader in AI | Taking risk assessments to another level | FDA clears software for real-time TAVR guidance

Cardiology continues to be one of the most influential healthcare specialties when it comes to utilizing artificial intelligence. 

Allen Taylor, MD, thinks AI-powered plaque evaluations can make a substantial impact on patient care. 

Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

Caranx Medical is focused on using AI, robotics and other advanced technologies to expand patient access to life-saving procedures. This new software, for example, helps guide cardiologists through complex TAVR procedures.

Philips has launched a new 'AI Marketplace' that expands access to third-party diagnostic tools. The company's goal is to put a variety of offerings into one convenient location for clinicians.

The first FDA-cleared AI model of its kind was found to be an accurate screening tool for cardiac amyloidosis.

"Using AI for tasks like CAC detection can help shift medicine from a reactive approach to the proactive prevention of disease," one researcher said.